**The Trump administration advanced partial marijuana rescheduling in April 2026 via Acting Attorney General order, moving FDA-approved products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act.** A new DEA administrative hearing on broader rescheduling of all botanical marijuana to Schedule III opened June 29, 2026, and was set to conclude by mid-July, with participants limited to opponents including Smart Approaches to Marijuana and several states. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs, while D.C. Circuit litigation challenges the April action but a September 9 ruling denied a stay, keeping partial rescheduling intact. These steps, alongside a December 2025 executive order for expedited review, shape trader views on timelines for full rescheduling amid ongoing legal and procedural hurdles.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update$810,510 Vol.
September 30
<1%
December 31
16%
$810,510 Vol.
September 30
<1%
December 31
16%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Binuksan ang Market: Jul 31, 2026, 5:46 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...**The Trump administration advanced partial marijuana rescheduling in April 2026 via Acting Attorney General order, moving FDA-approved products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act.** A new DEA administrative hearing on broader rescheduling of all botanical marijuana to Schedule III opened June 29, 2026, and was set to conclude by mid-July, with participants limited to opponents including Smart Approaches to Marijuana and several states. The DEA has defended the proposal in post-hearing briefs, citing accepted medical use and safety data from state programs, while D.C. Circuit litigation challenges the April action but a September 9 ruling denied a stay, keeping partial rescheduling intact. These steps, alongside a December 2025 executive order for expedited review, shape trader views on timelines for full rescheduling amid ongoing legal and procedural hurdles.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update



Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong